Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number.

<h4>Background</h4>We have previously identified genome-wide DNA methylation changes in a cell line model of breast cancer metastasis. These complex epigenetic changes that we observed, along with concurrent karyotype analyses, have led us to hypothesize that complex genomic alterations...

Full description

Bibliographic Details
Main Authors: Joseph Andrews, Wendy Kennette, Jenna Pilon, Alexandra Hodgson, Alan B Tuck, Ann F Chambers, David I Rodenhiser
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20084286/?tool=EBI
_version_ 1818827071590236160
author Joseph Andrews
Wendy Kennette
Jenna Pilon
Alexandra Hodgson
Alan B Tuck
Ann F Chambers
David I Rodenhiser
author_facet Joseph Andrews
Wendy Kennette
Jenna Pilon
Alexandra Hodgson
Alan B Tuck
Ann F Chambers
David I Rodenhiser
author_sort Joseph Andrews
collection DOAJ
description <h4>Background</h4>We have previously identified genome-wide DNA methylation changes in a cell line model of breast cancer metastasis. These complex epigenetic changes that we observed, along with concurrent karyotype analyses, have led us to hypothesize that complex genomic alterations in cancer cells (deletions, translocations and ploidy) are superimposed over promoter-specific methylation events that are responsible for gene-specific expression changes observed in breast cancer metastasis.<h4>Methodology/principal findings</h4>We undertook simultaneous high-resolution, whole-genome analyses of MDA-MB-468GFP and MDA-MB-468GFP-LN human breast cancer cell lines (an isogenic, paired lymphatic metastasis cell line model) using Affymetrix gene expression (U133), promoter (1.0R), and SNP/CNV (SNP 6.0) microarray platforms to correlate data from gene expression, epigenetic (DNA methylation), and combination copy number variant/single nucleotide polymorphism microarrays. Using Partek Software and Ingenuity Pathway Analysis we integrated datasets from these three platforms and detected multiple hypomethylation and hypermethylation events. Many of these epigenetic alterations correlated with gene expression changes. In addition, gene dosage events correlated with the karyotypic differences observed between the cell lines and were reflected in specific promoter methylation patterns. Gene subsets were identified that correlated hyper (and hypo) methylation with the loss (or gain) of gene expression and in parallel, with gene dosage losses and gains, respectively. Individual gene targets from these subsets were also validated for their methylation, expression and copy number status, and susceptible gene pathways were identified that may indicate how selective advantage drives the processes of tumourigenesis and metastasis.<h4>Conclusions/significance</h4>Our approach allows more precisely profiling of functionally relevant epigenetic signatures that are associated with cancer progression and metastasis.
first_indexed 2024-12-19T00:37:44Z
format Article
id doaj.art-083ed21a7a92410faf37d5733e161a66
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-19T00:37:44Z
publishDate 2010-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-083ed21a7a92410faf37d5733e161a662022-12-21T20:44:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-01-0151e866510.1371/journal.pone.0008665Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number.Joseph AndrewsWendy KennetteJenna PilonAlexandra HodgsonAlan B TuckAnn F ChambersDavid I Rodenhiser<h4>Background</h4>We have previously identified genome-wide DNA methylation changes in a cell line model of breast cancer metastasis. These complex epigenetic changes that we observed, along with concurrent karyotype analyses, have led us to hypothesize that complex genomic alterations in cancer cells (deletions, translocations and ploidy) are superimposed over promoter-specific methylation events that are responsible for gene-specific expression changes observed in breast cancer metastasis.<h4>Methodology/principal findings</h4>We undertook simultaneous high-resolution, whole-genome analyses of MDA-MB-468GFP and MDA-MB-468GFP-LN human breast cancer cell lines (an isogenic, paired lymphatic metastasis cell line model) using Affymetrix gene expression (U133), promoter (1.0R), and SNP/CNV (SNP 6.0) microarray platforms to correlate data from gene expression, epigenetic (DNA methylation), and combination copy number variant/single nucleotide polymorphism microarrays. Using Partek Software and Ingenuity Pathway Analysis we integrated datasets from these three platforms and detected multiple hypomethylation and hypermethylation events. Many of these epigenetic alterations correlated with gene expression changes. In addition, gene dosage events correlated with the karyotypic differences observed between the cell lines and were reflected in specific promoter methylation patterns. Gene subsets were identified that correlated hyper (and hypo) methylation with the loss (or gain) of gene expression and in parallel, with gene dosage losses and gains, respectively. Individual gene targets from these subsets were also validated for their methylation, expression and copy number status, and susceptible gene pathways were identified that may indicate how selective advantage drives the processes of tumourigenesis and metastasis.<h4>Conclusions/significance</h4>Our approach allows more precisely profiling of functionally relevant epigenetic signatures that are associated with cancer progression and metastasis.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20084286/?tool=EBI
spellingShingle Joseph Andrews
Wendy Kennette
Jenna Pilon
Alexandra Hodgson
Alan B Tuck
Ann F Chambers
David I Rodenhiser
Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number.
PLoS ONE
title Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number.
title_full Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number.
title_fullStr Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number.
title_full_unstemmed Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number.
title_short Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number.
title_sort multi platform whole genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20084286/?tool=EBI
work_keys_str_mv AT josephandrews multiplatformwholegenomemicroarrayanalysesrefinetheepigeneticsignatureofbreastcancermetastasiswithgeneexpressionandcopynumber
AT wendykennette multiplatformwholegenomemicroarrayanalysesrefinetheepigeneticsignatureofbreastcancermetastasiswithgeneexpressionandcopynumber
AT jennapilon multiplatformwholegenomemicroarrayanalysesrefinetheepigeneticsignatureofbreastcancermetastasiswithgeneexpressionandcopynumber
AT alexandrahodgson multiplatformwholegenomemicroarrayanalysesrefinetheepigeneticsignatureofbreastcancermetastasiswithgeneexpressionandcopynumber
AT alanbtuck multiplatformwholegenomemicroarrayanalysesrefinetheepigeneticsignatureofbreastcancermetastasiswithgeneexpressionandcopynumber
AT annfchambers multiplatformwholegenomemicroarrayanalysesrefinetheepigeneticsignatureofbreastcancermetastasiswithgeneexpressionandcopynumber
AT davidirodenhiser multiplatformwholegenomemicroarrayanalysesrefinetheepigeneticsignatureofbreastcancermetastasiswithgeneexpressionandcopynumber